Medicare beneficiaries now have access to USDA organic CBD products through participating health care organizations, a first-of-its-kind federal initiative that brings rigorously tested hemp products into the mainstream health care system. Starting in April 2026, eligible Medicare patients can receive up to $500 per year in organic hemp products as part of a clinical consultation with their physician, administered through the Center for Medicare and Medicaid Innovation (CMMI) pilot program .

What Is the CMMI Hemp Pilot, and Who Can Access It?

The Substance Access Beneficiary Engagement Incentive (BEI) represents the first time hemp-derived CBD products will be made available to Medicare beneficiaries through participating Accountable Care Organizations (ACOs). The program is available to patients enrolled in three CMS models: ACO REACH, the Enhancing Oncology Model (EOM), and the Long-term Enhanced ACO Design (LEAD) . Participating organizations can elect to offer eligible beneficiaries hemp products furnished directly by a qualified physician as part of a documented clinical consultation. Importantly, Medicare itself does not pay for the products; the cost is borne by the participating ACO as part of their model participation .

The program is being rolled out through a network of 68,000 health care provider locations nationwide, thanks to an exclusive contract between Cornbread Hemp and Alliant Purchasing, a national Group Purchasing Organization (GPO) that has served health care providers for more than 35 years and leverages more than $82 billion in collective buying power on behalf of its membership .

What Quality Standards Must Hemp Products Meet in This Program?

The Centers for Medicare and Medicaid Services (CMS) has established strict eligibility standards for hemp products used in the BEI program. These requirements ensure that only the safest, most rigorously tested products reach Medicare beneficiaries . Products must meet the following criteria:

• THC Content: No more than 0.3% delta-9 THC, the psychoactive compound in cannabis
• Product Format: Exclude inhalable formats such as vapes or smokable products
• Serving Size: No more than 3 milligrams per serving of tetrahydrocannabinol (THC) in orally administered form
• Cannabinoid Purity: Exclude any cannabinoids not naturally produced by the cannabis plant
• Independent Testing: All products must be tested by an independent third party for potency, contaminants, and microbial hazards

Cornbread Hemp, the exclusive supplier selected for this program, meets and exceeds these standards with credentials that institutional health care demands. The company has offered USDA certified organic CBD products since 2019, with 19 different certified organic products available . All products are manufactured in a Good Manufacturing Practice (GMP) certified facility in Louisville, Kentucky, and the company maintains a clean regulatory record with no FDA warning letters, product recalls, or enforcement actions in its history .

Why Does USDA Organic Certification Matter for Hemp Products?

USDA organic certification provides federal quality assurance that goes beyond standard CBD testing. Organic certification requires that hemp is grown without synthetic pesticides, herbicides, or fertilizers, and that the entire production process meets rigorous federal standards. For Cornbread Hemp, this means their products are sourced exclusively from Kentucky-grown hemp flowers using a proprietary "Flower-Only" extraction process that preserves a fuller spectrum of naturally occurring cannabinoids, terpenes, and flavonoids .

"Cornbread Hemp products are organically certified, rigorously lab tested, and manufactured according to GMP. Such quality is important for patients, particularly cancer patients," said Leslie Mudd, a board-certified oncology pharmacist with 20 years of clinical experience at the James Graham Brown Cancer Center at the University of Louisville.

Leslie Mudd, PharmD, Board-Certified Oncology Pharmacist, James Graham Brown Cancer Center

Mudd chairs Cornbread Hemp's Medical Advisory Board and brings direct clinical insight into oncology patient needs and treatment protocols. Her involvement underscores the company's commitment to meeting the safety standards that health care providers require when recommending hemp products to vulnerable patient populations .

How Will Real-World Data Shape the Future of Hemp in Medicare?

As the CMMI pilot generates patient data on CBD use among Medicare beneficiaries, Cornbread Hemp has established a preferred partnership with Realm of Caring, a nonprofit organization dedicated to cannabinoid research, patient education, and real-world outcomes data. This partnership ensures that the evidence infrastructure will define best practices for CBD use within the Medicare system for years to come .

"By working together, we can build the real-world evidence needed to guide safer use, inform providers and ensure patient voices remain central to the future of cannabinoid care," explained Sasha Kalcheff-Korn, Executive Director at Realm of Caring.

Sasha Kalcheff-Korn, Executive Director, Realm of Caring

This data collection approach is significant because it respects patient experiences and lived knowledge while building the clinical evidence base that will guide future policy decisions. The partnership ensures that Medicare beneficiaries are not only heard but also compensated for their participation in research .

What Does This Mean for Clean Living and Environmental Health?

The inclusion of USDA organic hemp products in the Medicare system represents a broader shift toward plant-based, chemically clean alternatives in mainstream health care. By requiring organic certification, the program prioritizes products grown without synthetic pesticides or fertilizers, reducing both the chemical burden on consumers and the environmental impact of agricultural production. This alignment between federal health care policy and organic farming standards signals growing recognition that clean, minimally processed products can play a meaningful role in patient care .

The program also supports domestic agricultural production. Cornbread Hemp operates a production facility in Louisville, employing more than 100 Kentucky workers. In early 2025, Kentucky Governor Andy Beshear recognized the company's expansion with a $1 million investment commitment and 50 new jobs, backed by a Kentucky Business Investment incentive agreement .

Key Takeaways

This landmark CMMI pilot program represents a historic moment for both the hemp industry and Medicare beneficiaries seeking cleaner, plant-based wellness options. The program's emphasis on USDA organic certification, rigorous third-party testing, and clinical oversight ensures that patients receive products that meet the highest safety and quality standards. As the program launches in April 2026, the real-world data collected will shape how hemp-derived CBD products are integrated into mainstream health care for years to come.

" }